The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph. But the excitement around the drug has receded. Why is Biogen’s drug so controversial? Watch the full video here:
's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every year.
Physicians have been split over whether clinical trial data proves the monoclonal antibody actually slows cognitive decline. What's more, Medicare is debating whether to cover seniors on the government-run insurance program for Alzheimer's treatments, a decision that is crucial to their profit potential.
Meanwhile, shares of the Cambridge, Massachusetts-based biotech have cratered roughly 40% since the beginning of June. Given Aduhelm's lackluster debut, as well as generic competition for Biogen's other drugs, the company nowcontroversial